What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

Part of paid clinical trials in Flagstaff, Arizona.

Sponsor
Northern Arizona University
Study ID
NCT07452094
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Experimental
  • Placebo - Control

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • EXERCISE TRAINING WITH OR WITHOUT MEDICATION — DRUG
    Cycling exercise with group III/IV afferent feedback blocked via drug

Study Details

Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.

Key Dates

Start date
Apr 1, 2026
Status verified
Dec 2025
Primary completion
Dec 31, 2026
Completion
Apr 1, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo-control
    Exercise with saline injection
  • Experimental: Group III/IV afferent blockade
    Feedback from group III/IV afferents is blocked

Primary Outcome Measure

Airway resistance [ Time Frame: 2 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northern Arizona UniversityFlagstaffArizona86011
TRAVIS D GIBBONS, PhD
[email protected]
9282558769
RILEY CONNOR, MS (SUB_INVESTIGATOR)
TRAVIS D GIBBONS, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Flagstaff, AZ

By research site
Northern Arizona University· Flagstaff, AZ

Related Studies